Rallybio reports Q4 EPS (25c), consensus (30c)

Reports Q4 revenue was $38K and $600K for the year ended December 3 compared to no revenue in the same periods in 2023. The increase in revenue for both the fourth quarter of 2024 and the year ended December 31, was related to Rallybio’s (RLYB) entrance into the collaboration agreement with Johnson & Johnson(JNJ) in the second quarter of 2024 and the recognition of revenue related to the collaboration’s performance obligations. .”We are pleased with our strong execution in 2024, and look forward to reporting on our planned milestones in 2025,” said Stephen Uden, M.D., Chief Executive Officer of Rallybio. “Dosing in our RLYB212 Phase 2 trial is underway, our differentiated C5 inhibitor, RLYB116, is on track to enter a confirmatory pharmacokinetic/pharmacodynamic study in the second quarter, and our potentially best-in-class ENPP1 inhibitor for patients with hypophosphatasia, REV102, is advancing toward Phase 1 in 2026. Through exceptional execution of these programs and continued financial discipline, we are laser focused on driving value for Rallybio in 2025 and positioning the Company for sustained growth and success in the future.”